SAB Biotherapeutics, Inc.
SABS
$3.67
$0.030.82%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 18.74M | -37.06M | -34.28M | -34.11M | -45.57M |
| Total Depreciation and Amortization | 3.10M | 3.31M | 3.59M | 4.79M | 4.95M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -61.12M | 757.50K | -2.19M | -2.68M | 3.25M |
| Change in Net Operating Assets | 1.75M | 2.22M | 1.54M | -2.30M | -842.00K |
| Cash from Operations | -37.53M | -30.77M | -31.34M | -34.29M | -38.21M |
| Capital Expenditure | -55.40K | -155.70K | -208.20K | -337.30K | -349.80K |
| Sale of Property, Plant, and Equipment | 500.00 | 500.00 | 500.00 | -- | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -110.61M | 18.20M | 24.28M | -11.63M | -21.01M |
| Cash from Investing | -110.67M | 18.05M | 24.07M | -11.96M | -21.36M |
| Total Debt Issued | 516.00K | 516.00K | 516.00K | 516.00K | 765.20K |
| Total Debt Repaid | -655.80K | -1.27M | -1.35M | -1.42M | -1.44M |
| Issuance of Common Stock | 168.73M | 0.00 | 0.00 | 20.40K | 59.68M |
| Repurchase of Common Stock | -31.90K | -27.00K | -27.00K | -24.90K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | 7.50M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -25.00K | -93.70K | -261.10K | -261.10K |
| Cash from Financing | 168.56M | -804.90K | -952.10K | -1.17M | 66.25M |
| Foreign Exchange rate Adjustments | -104.30K | -19.30K | -170.40K | -241.20K | 65.60K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 20.25M | -13.55M | -8.39M | -47.67M | 6.75M |